Nkarta (NASDAQ:NKTX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Nkarta (NASDAQ:NKTX) from a hold rating to a sell rating in a report issued on Sunday morning.

A number of other research analysts also recently commented on NKTX. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th. Stifel Nicolaus reduced their price target on Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research note on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Nkarta Stock Up 3.8%

NASDAQ:NKTX opened at $1.90 on Friday. Nkarta has a twelve month low of $1.31 and a twelve month high of $2.74. The firm has a market capitalization of $134.96 million, a price-to-earnings ratio of -1.38 and a beta of 0.80. The stock’s 50 day moving average price is $2.05 and its two-hundred day moving average price is $2.00.

Nkarta (NASDAQ:NKTX) last released its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. As a group, analysts anticipate that Nkarta will post -1.7 earnings per share for the current year.

Institutional Trading of Nkarta

Several hedge funds have recently added to or reduced their stakes in NKTX. Alyeska Investment Group L.P. grew its holdings in Nkarta by 54.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company’s stock valued at $3,800,000 after buying an additional 730,260 shares in the last quarter. Monaco Asset Management SAM grew its stake in shares of Nkarta by 24.5% in the third quarter. Monaco Asset Management SAM now owns 1,970,910 shares of the company’s stock valued at $4,080,000 after acquiring an additional 387,538 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Nkarta by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after acquiring an additional 10,065 shares in the last quarter. AWM Investment Company Inc. increased its position in Nkarta by 150.0% during the first quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company’s stock worth $1,840,000 after acquiring an additional 600,000 shares during the period. Finally, Millennium Management LLC acquired a new stake in Nkarta in the 3rd quarter worth about $1,549,000. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.